{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:26:26Z","timestamp":1763447186831,"version":"3.45.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This article reports a rare case of a patient with POEMS syndrome who developed secondary myelodysplastic syndrome (MDS) two years after undergoing autologous stem cell transplantation (ASCT). The patient was initially misdiagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) due to symptoms of limb numbness and weakness. Two years later, the diagnosis was corrected to POEMS syndrome. After induction therapy with the lenalidomide-dexamethasone (RD) regimen, ASCT is performed and partial remission is achieved. And lenalidomide was used for maintenance therapy. Over a year later, he was infected with SARS-CoV-2 and subsequently developed pancytopenia. Bone marrow routine revealed increased myeloblasts with multilineage dysplasia, and next-generation sequencing (NGS) found a TP53 mutation, leading to the diagnosis of secondary MDS. The pathogenesis of secondary MDS in POEMS syndrome is discussed from three aspects: cytotoxic therapy, genetic predisposition, and SARS-CoV-2 infection. This case underscores the importance of prolonged surveillance for secondary myeloid neoplasms (sMN) in POEMS patients and suggests that early genomic profiling and individualized treatment may improve outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1711447","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:22:05Z","timestamp":1763446925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Miaoya","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature","volume":"59","author":"Bardwick","year":"1980","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2007.07.004","article-title":"POEMS syndrome","volume":"21","author":"Dispenzieri","year":"2007","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.168","article-title":"Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome","volume":"31","author":"Wang","year":"2017","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285282","article-title":"Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy","volume":"109","author":"Gao","year":"2024","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","article-title":"NCCN guidelines\u00ae Insights: myelodysplastic syndromes, version 2.2025","volume":"23","author":"Greenberg","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.344","article-title":"Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment","volume":"30","author":"Kourelis","year":"2016","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20241219-00578","article-title":"Chinese expert consensus on the diagnosis and treatment of POEMS syndrome (2025)","volume":"46","year":"2025","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: Update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009940","article-title":"Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study","volume":"95","author":"Keddie","year":"2020","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02489-z","article-title":"Capillary leak phenotype as a major cause of death in patients with POEMS syndrome","volume":"39","author":"Lee","year":"2025","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.leukres.2016.09.017","article-title":"Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome","volume":"50","author":"Wang","year":"2016","journal-title":"Leuk Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304874","article-title":"Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome","volume":"84","author":"Sekiguchi","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9068-4","article-title":"An update on the diagnosis and management of the polyneuropathy of POEMS syndrome","volume":"266","author":"Cerri","year":"2019","journal-title":"J Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25100","article-title":"A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome","volume":"93","author":"Li","year":"2018","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14497","article-title":"Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen","volume":"181","author":"He","year":"2018","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2014.11.023","article-title":"Expert consensus on diagnosis and treatment of myelodysplastic syndrome (2014)","volume":"35","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Ad\u00e8s","year":"2014","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051483","article-title":"The secondary myelodysplastic neoplasms (MDS) jigsaw","volume":"15","author":"Calvete","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030508","article-title":"Unveiling myelodysplastic syndromes: exploring pathogenic mechanisms and therapeutic advances","volume":"17","author":"Thalambedu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary Malignancies in multiple myeloma: A review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466961","article-title":"Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-021-00454-y","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Nadiminti","year":"2021","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1721","article-title":"Investigating additional Malignancy rates and prognostic factors in multiple myeloma patients: a Surveillance, Epidemiology, and End Results (SEER) database retrospective cohort study","volume":"14","author":"Dong","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.09.023","article-title":"Second primary Malignancies after autologous hematopoietic cell transplantation for multiple myeloma","volume":"19","author":"Krishnan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtct.2023.06.015","article-title":"Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation","volume":"30","author":"Yalniz","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197011192832101","article-title":"Multiple myeloma and acute myelomonocytic leukemia","volume":"283","author":"Kyle","year":"1970","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05985-5","article-title":"Therapy-related myeloid neoplasms: a real-world pharmacovigilance analysis (1970-2023)","volume":"103","author":"Gaddam","year":"2024","journal-title":"Ann Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009212","article-title":"Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal","volume":"7","author":"Geyer","year":"2023","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary Malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e13050","DOI":"10.1111\/eci.13050","article-title":"Increasing therapy-related myeloid neoplasms in multiple myeloma","volume":"49","author":"Fern\u00e1ndez-Caballero","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53 -mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100166","article-title":"Clinicopathologic features of therapy-related myeloid neoplasms in patients with myeloma in the era of novel therapies","volume":"36","author":"Jelloul","year":"2023","journal-title":"Mod Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1563990","article-title":"Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms","volume":"15","author":"Costa","year":"2025","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1217527","article-title":"Secondary Malignancies in patients with multiple myeloma, Waldenstr\u00f6m macroglobulinemia and monoclonal gammopathy of undetermined significance","volume":"58","author":"Castillo","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Varettoni","year":"2012","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17\u2009315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003382","article-title":"Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma","volume":"135","author":"Maia","year":"2020","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284050","article-title":"Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes","volume":"109","author":"Escure","year":"2024","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02707-2","article-title":"Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma","volume":"39","author":"Cooperrider","year":"2025","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05803-y","article-title":"The role of clonal progression leading to the development of therapy-related myeloid neoplasms","volume":"103","author":"Guarnera","year":"2024","journal-title":"Ann Hematol"},{"key":"B53","article-title":"Infectious pathogens and hematologic Malignancy","volume":"14","author":"Sadrzadeh","year":"2012","journal-title":"Discov Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.44","article-title":"Coronavirus disease 2019 induces multi-lineage, morphologic changes in peripheral blood cells","volume":"1","author":"L\u00fcke","year":"2020","journal-title":"EJHaem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2020.2020.0262","article-title":"Peripheral blood smear findings in COVID-19","volume":"37","author":"Ahnach","year":"2020","journal-title":"Turk J Haematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-03069-1","article-title":"Myelodysplastic syndrome in a kidney transplant recipient after SARS-CoV-2 infection: can SARS-CoV-2 induce myelodysplastic syndrome","volume":"54","author":"Juric","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"eabc8511","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0925-5710(98)00051-6","article-title":"Hypothesis: myelodysplastic syndromes may have a viral etiology","volume":"68","author":"Raza","year":"1998","journal-title":"Int J Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/BF02821935","article-title":"Initial transforming event in myelodysplastic syndromes may be viral: case for cytomegalovirus","volume":"15","author":"Raza","year":"1998","journal-title":"Med Oncol"},{"key":"B62","article-title":"Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population","volume":"57","author":"Karlic","year":"1997","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1287839","article-title":"Stem cell transplantation in 6 children with parvovirus B19- induced severe aplastic anaemia or myelodysplastic syndrome","volume":"223","author":"Urban","year":"2011","journal-title":"Klin Padiatr"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20667","article-title":"Human herpesvirus 6 infection and transient acquired myelodysplasia in children","volume":"47","author":"Kagialis-Girard","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2021.01.005","article-title":"High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19","volume":"51","author":"Simonnet","year":"2021","journal-title":"Infect Dis Now"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e2021274","DOI":"10.4322\/acr.2021.274","article-title":"Myelodysplastic syndrome in a 30-year-old man with coronavirus disease 2019 (COVID-19): a diagnostic challenge","volume":"11","author":"Qing","year":"2021","journal-title":"Autops Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:22:09Z","timestamp":1763446929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1711447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2025.1711447"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1711447","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1711447"}}